{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"40.7","upperLimit":"64.7","value":"52.8"},{"groupId":"OG001","lowerLimit":"12.0","upperLimit":"45.1","value":"26.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"description":"The DCR was defined as the percentage of participants in the analysis population who have achieved a CR, PR or SD response prior to PD. CR is the disappearance of all evidence of disease and PR is the regression of measurable disease and no new sites. SD is the failure to attain CR/PR or PD. PD is the appearance any new lesion or increase by ≥ 50% of previously involved site from nadir. Participants with missing data were considered non-responders.","dispersionType":"90% Confidence Interval","groups":[{"description":"Pembrolizumab 200 mg every 3 weeks (Q3W), intravenous infusion (IV) on Day 1 of each 3-week cycle for up to 35 administrations (approximately 2 years).","id":"OG000","title":"Pembrolizumab: Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)"},{"description":"Pembrolizumab 200 mg Q3W, IV on Day 1 of each 3-week cycle for up to 35 administrations (approximately 2 years).","id":"OG001","title":"Pembrolizumab: Relapsed or Refractory Richter Syndrome (rrRS)"}],"paramType":"NUMBER","populationDescription":"The analysis population included all participants who received at least one dose of study medication (pembrolizumab).","reportingStatus":"POSTED","timeFrame":"Up to approximately 27 months (Database Cutoff Date: 28MAY2019)","title":"Disease Control Rate (DCR) Based on IWG Response Assessment Criteria by Investigator Assessment","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}